{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,30]],"date-time":"2026-08-30T09:18:46Z","timestamp":1788081526657,"version":"build-2784847793"},"reference-count":47,"publisher":"American Society of Hematology","issue":"4","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2018,2,27]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>Eltrombopag is currently the only US Food and Drug Administration\u2013approved thrombopoietin receptor agonist for the treatment of chronic immune thrombocytopenia (ITP) in children. This oral, once-per-day therapy has shown favorable efficacy and adverse effect profiles in children. Two multicenter, double-blind, placebo controlled clinical trials (PETIT [Efficacy and Safety Study of Eltrombopag in Pediatric Patients With Thrombocytopenia From Chronic Idiopathic Thrombocytopenic Purpura (ITP)] and PETIT2 [Study of a New Medication for Childhood Chronic Immune Thrombocytopenia (ITP), a Blood Disorder of Low Platelet Counts That Can Lead to Bruising Easily, Bleeding Gums, and\/or Bleeding Inside the Body]) demonstrated efficacy in raising platelet counts, reducing bleeding, and reducing the need for concomitant ITP therapies with relatively few adverse effects. The most commonly reported drug-related adverse effects include headache, nausea, and hepatobiliary laboratory abnormalities. Long-term safety data in children are limited, and studies in adults have not revealed a clinically significant increased incidence of thrombosis, marrow fibrosis, or cataract formation. Eltrombopag has also been approved for treating refractory severe aplastic anemia (AA) and has potential for expanded use in ITP and severe AA as well as in other conditions associated with thrombocytopenia.<\/jats:p>","DOI":"10.1182\/bloodadvances.2017010660","type":"journal-article","created":{"date-parts":[[2018,2,28]],"date-time":"2018-02-28T01:35:12Z","timestamp":1519781712000},"page":"454-461","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":89,"title":["Eltrombopag for use in children with immune thrombocytopenia"],"prefix":"10.1182","volume":"2","author":[{"given":"Taylor Olmsted","family":"Kim","sequence":"first","affiliation":[{"name":"Department of Pediatrics, Section of Hematology\/Oncology, Baylor College of Medicine, Houston, TX;"},{"name":"Texas Children\u2019s Cancer and Hematology Centers, Houston, TX;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jenny","family":"Despotovic","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, Section of Hematology\/Oncology, Baylor College of Medicine, Houston, TX;"},{"name":"Texas Children\u2019s Cancer and Hematology Centers, Houston, TX;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michele P.","family":"Lambert","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA; and"},{"name":"Division of Hematology, The Children\u2019s Hospital of Philadelphia, Philadelphia, PA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","published-online":{"date-parts":[[2018,2,27]]},"reference":[{"issue":"4","key":"2019111616305145200_B1","first-page":"473","article-title":"Acute prolonged thrombocytosis in mice induced by thrombocythaemic sera; a possible human thrombopoietin; a preliminary communication","volume":"11","author":"Cserhati","year":"1958","journal-title":"Acta Med Acad Sci Hung"},{"issue":"7","key":"2019111616305145200_B2","doi-asserted-by":"crossref","first-page":"1117","DOI":"10.1016\/0092-8674(94)90450-2","article-title":"Identification and cloning of a megakaryocyte growth and development factor that is a ligand for the cytokine receptor Mpl","volume":"77","author":"Bartley","year":"1994","journal-title":"Cell"},{"issue":"6481","key":"2019111616305145200_B3","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1038\/369533a0","article-title":"Stimulation of megakaryocytopoiesis and thrombopoiesis by the c-Mpl ligand","volume":"369","author":"de Sauvage","year":"1994","journal-title":"Nature"},{"issue":"23","key":"2019111616305145200_B4","doi-asserted-by":"crossref","first-page":"11104","DOI":"10.1073\/pnas.91.23.11104","article-title":"The purification of megapoietin: a physiological regulator of megakaryocyte growth and platelet production","volume":"91","author":"Kuter","year":"1994","journal-title":"Proc Natl Acad Sci USA"},{"issue":"26","key":"2019111616305145200_B5","doi-asserted-by":"crossref","first-page":"13023","DOI":"10.1073\/pnas.91.26.13023","article-title":"Human thrombopoietin: gene structure, cDNA sequence, expression, and chromosomal localization","volume":"91","author":"Foster","year":"1994","journal-title":"Proc Natl Acad Sci USA"},{"issue":"6481","key":"2019111616305145200_B6","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1038\/369565a0","article-title":"Cloning and expression of murine thrombopoietin cDNA and stimulation of platelet production in vivo","volume":"369","author":"Lok","year":"1994","journal-title":"Nature"},{"issue":"9037","key":"2019111616305145200_B7","doi-asserted-by":"crossref","first-page":"1279","DOI":"10.1016\/S0140-6736(96)04471-6","article-title":"Thrombopoietic effects of pegylated recombinant human megakaryocyte growth and development factor (PEG-rHuMGDF) in patients with advanced cancer","volume":"348","author":"Basser","year":"1996","journal-title":"Lancet"},{"issue":"11","key":"2019111616305145200_B8","doi-asserted-by":"crossref","first-page":"3694","DOI":"10.1182\/blood.V94.11.3694","article-title":"A randomized, double-blind, placebo-controlled study with pegylated recombinant human megakaryocyte growth and development factor (PEG-rHuMGDF) as an adjunct to chemotherapy for adults with de novo acute myeloid leukemia","volume":"94","author":"Archimbaud","year":"1999","journal-title":"Blood"},{"issue":"5","key":"2019111616305145200_B9","doi-asserted-by":"crossref","first-page":"1339","DOI":"10.1182\/blood.V98.5.1339","article-title":"Thrombopoietin therapy increases platelet yields in healthy platelet donors","volume":"98","author":"Kuter","year":"2001","journal-title":"Blood"},{"issue":"8","key":"2019111616305145200_B10","doi-asserted-by":"crossref","first-page":"2530","DOI":"10.1182\/blood.V95.8.2530","article-title":"A double-blind, placebo-controlled trial of pegylated recombinant human megakaryocyte growth and development factor as an adjunct to induction and consolidation therapy for patients with acute myeloid leukemia","volume":"95","author":"Schiffer","year":"2000","journal-title":"Blood"},{"issue":"9","key":"2019111616305145200_B11","doi-asserted-by":"crossref","first-page":"673","DOI":"10.7326\/0003-4819-126-9-199705010-00001","article-title":"Stimulation of megakaryocyte and platelet production by a single dose of recombinant human thrombopoietin in patients with cancer","volume":"126","author":"Vadhan-Raj","year":"1997","journal-title":"Ann Intern Med"},{"issue":"3","key":"2019111616305145200_B12","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1046\/j.1537-2995.2002.00056.x","article-title":"Whatever happened to thrombopoietin?","volume":"42","author":"Kuter","year":"2002","journal-title":"Transfusion"},{"issue":"12","key":"2019111616305145200_B13","doi-asserted-by":"crossref","first-page":"3241","DOI":"10.1182\/blood.V98.12.3241","article-title":"Thrombocytopenia caused by the development of antibodies to thrombopoietin","volume":"98","author":"Li","year":"2001","journal-title":"Blood"},{"issue":"2","key":"2019111616305145200_B14","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1007\/s12185-012-1124-8","article-title":"A multicenter randomized controlled trial of recombinant human thrombopoietin treatment in patients with primary immune thrombocytopenia","volume":"96","author":"Wang","year":"2012","journal-title":"Int J Hematol"},{"issue":"9","key":"2019111616305145200_B15","doi-asserted-by":"crossref","first-page":"1097","DOI":"10.1182\/blood-2017-01-761262","article-title":"A novel recombinant human thrombopoietin therapy for the management of immune thrombocytopenia in pregnancy","volume":"130","author":"Kong","year":"2017","journal-title":"Blood"},{"issue":"14","key":"2019111616305145200_B16","doi-asserted-by":"crossref","first-page":"2243","DOI":"10.1517\/14656566.2015.1085512","article-title":"Eltrombopag for treatment of thrombocytopenia-associated disorders","volume":"16","author":"Merli","year":"2015","journal-title":"Expert Opin Pharmacother"},{"issue":"1","key":"2019111616305145200_B17","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1007\/s12185-013-1382-0","article-title":"The biology of thrombopoietin and thrombopoietin receptor agonists","volume":"98","author":"Kuter","year":"2013","journal-title":"Int J Hematol"},{"issue":"2","key":"2019111616305145200_B18","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1634\/stemcells.2008-0366","article-title":"Preclinical activity of eltrombopag (SB-497115), an oral, nonpeptide thrombopoietin receptor agonist","volume":"27","author":"Erickson-Miller","year":"2009","journal-title":"Stem Cells"},{"issue":"6","key":"2019111616305145200_B19","doi-asserted-by":"crossref","first-page":"1088","DOI":"10.1124\/dmd.110.037960","article-title":"Pharmacokinetics and hepatic uptake of eltrombopag, a novel platelet-increasing agent","volume":"39","author":"Takeuchi","year":"2011","journal-title":"Drug Metab Dispos"},{"issue":"4","key":"2019111616305145200_B20","doi-asserted-by":"crossref","first-page":"726","DOI":"10.1124\/dmd.113.054767","article-title":"Interaction of novel platelet-increasing agent eltrombopag with rosuvastatin via breast cancer resistance protein in humans","volume":"42","author":"Takeuchi","year":"2014","journal-title":"Drug Metab Dispos"},{"issue":"8","key":"2019111616305145200_B21","doi-asserted-by":"crossref","first-page":"e315","DOI":"10.1016\/S2352-3026(15)00114-3","article-title":"Eltrombopag for the treatment of children with persistent and chronic immune thrombocytopenia (PETIT): a randomised, multicentre, placebo-controlled study","volume":"2","author":"Bussel","year":"2015","journal-title":"Lancet Haematol"},{"issue":"22","key":"2019111616305145200_B22","doi-asserted-by":"crossref","first-page":"2237","DOI":"10.1056\/NEJMoa073275","article-title":"Eltrombopag for the treatment of chronic idiopathic thrombocytopenic purpura","volume":"357","author":"Bussel","year":"2007","journal-title":"N Engl J Med"},{"issue":"9763","key":"2019111616305145200_B23","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1016\/S0140-6736(10)60959-2","article-title":"Eltrombopag for management of chronic immune thrombocytopenia (RAISE): a 6-month, randomised, phase 3 study","volume":"377","author":"Cheng","year":"2011","journal-title":"Lancet"},{"issue":"10004","key":"2019111616305145200_B24","doi-asserted-by":"crossref","first-page":"1649","DOI":"10.1016\/S0140-6736(15)61107-2","article-title":"Eltrombopag for children with chronic immune thrombocytopenia (PETIT2): a randomised, multicentre, placebo-controlled trial","volume":"386","author":"Grainger","year":"2015","journal-title":"Lancet"},{"key":"2019111616305145200_B25","doi-asserted-by":"crossref","DOI":"10.1016\/j.jpeds.2007.01.037","article-title":"Validity, reliability, and responsiveness of a new measure of health-related quality of life in children with immune thrombocytopenic purpura: the Kids\u2019 ITP Tools","author":"Klaassen","year":"2007"},{"issue":"8","key":"2019111616305145200_B26","doi-asserted-by":"crossref","first-page":"869","DOI":"10.1007\/s40265-016-0581-4","article-title":"Eltrombopag: A Review in Paediatric Chronic Immune Thrombocytopenia","volume":"76","author":"Burness","year":"2016","journal-title":"Drugs"},{"issue":"9664","key":"2019111616305145200_B27","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1016\/S0140-6736(09)60402-5","article-title":"Effect of eltrombopag on platelet counts and bleeding during treatment of chronic idiopathic thrombocytopenic purpura: a randomised, double-blind, placebo-controlled trial","volume":"373","author":"Bussel","year":"2009","journal-title":"Lancet"},{"key":"2019111616305145200_B28","year":"2015"},{"issue":"2","key":"2019111616305145200_B29","doi-asserted-by":"crossref","first-page":"171","DOI":"10.2174\/157488610790936196","article-title":"Safety of the thrombopoiesis-stimulating agents for the treatment of immune thrombocytopenia","volume":"5","author":"Cuker","year":"2010","journal-title":"Curr Drug Saf"},{"issue":"18","key":"2019111616305145200_B30","doi-asserted-by":"crossref","first-page":"3748","DOI":"10.1182\/blood-2009-05-224766","article-title":"Evaluation of bone marrow reticulin formation in chronic immune thrombocytopenia patients treated with romiplostim","volume":"114","author":"Kuter","year":"2009","journal-title":"Blood"},{"issue":"7","key":"2019111616305145200_B31","doi-asserted-by":"crossref","first-page":"598","DOI":"10.1002\/ajh.24011","article-title":"Evaluation of bone marrow reticulin in patients with chronic immune thrombocytopenia treated with eltrombopag: Data from the EXTEND study","volume":"90","author":"Brynes","year":"2015","journal-title":"Am J Hematol"},{"issue":"23","key":"2019111616305145200_B32","doi-asserted-by":"crossref","first-page":"2527","DOI":"10.1182\/blood-2017-04-748707","article-title":"Safety and efficacy of long-term treatment of chronic\/persistent ITP with eltrombopag: final results of the EXTEND study","volume":"130","author":"Wong","year":"2017","journal-title":"Blood"},{"issue":"8","key":"2019111616305145200_B33","first-page":"1128","article-title":"European consensus on grading bone marrow fibrosis and assessment of cellularity","volume":"90","author":"Thiele","year":"2005","journal-title":"Haematologica"},{"issue":"2","key":"2019111616305145200_B34","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1159\/000452992","article-title":"A 2-year, longitudinal, prospective study of the effects of eltrombopag on bone marrow in patients with chronic immune thrombocytopenia","volume":"137","author":"Brynes","year":"2017","journal-title":"Acta Haematol"},{"issue":"8","key":"2019111616305145200_B35","doi-asserted-by":"crossref","first-page":"1407","DOI":"10.1002\/pbc.26003","article-title":"Thrombopoietin receptor agonist use in children: Data From the Pediatric ITP Consortium of North America ICON2 Study","volume":"63","author":"Neunert","year":"2016","journal-title":"Pediatr Blood Cancer"},{"key":"2019111616305145200_B36","doi-asserted-by":"crossref","DOI":"10.1016\/j.jpeds.2014.03.060","article-title":"Thrombopoietic agents for the treatment of persistent and chronic immune thrombocytopenia in children","author":"Ramaswamy","year":"2014"},{"issue":"17","key":"2019111616305145200_B37","doi-asserted-by":"crossref","first-page":"1923","DOI":"10.1182\/blood-2016-10-740241","article-title":"Eltrombopag: a powerful chelator of cellular or extracellular iron(III) alone or combined with a second chelator","volume":"130","author":"Vlachodimitropoulou","year":"2017","journal-title":"Blood"},{"issue":"3","key":"2019111616305145200_B38","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1111\/jth.13602","article-title":"Eltrombopag, a thrombopoietin mimetic, crosses the blood-brain barrier and impairs iron-dependent hippocampal neuron dendrite development","volume":"15","author":"Bastian","year":"2017","journal-title":"J Thromb Haemost"},{"issue":"3","key":"2019111616305145200_B39","doi-asserted-by":"crossref","first-page":"E40","DOI":"10.1002\/ajh.23900","article-title":"Successful discontinuation of eltrombopag after complete remission in patients with primary immune thrombocytopenia","volume":"90","author":"Gonz\u00e1lez-L\u00f3pez","year":"2015","journal-title":"Am J Hematol"},{"issue":"2","key":"2019111616305145200_B40","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1182\/blood-2009-06-225565","article-title":"International consensus report on the investigation and management of primary immune thrombocytopenia","volume":"115","author":"Provan","year":"2010","journal-title":"Blood"},{"issue":"3","key":"2019111616305145200_B41","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1007\/s00277-016-2896-3","article-title":"Sequential treatment with thrombopoietin-receptor agonists (TPO-RAs) in immune thrombocytopenia (ITP): experience in our center","volume":"96","author":"Gonz\u00e1lez","year":"2017","journal-title":"Ann Hematol"},{"issue":"16","key":"2019111616305145200_B42","doi-asserted-by":"crossref","first-page":"1540","DOI":"10.1056\/NEJMoa1613878","article-title":"Eltrombopag added to standard immunosuppression for aplastic anemia","volume":"376","author":"Townsley","year":"2017","journal-title":"N Engl J Med"},{"issue":"1","key":"2019111616305145200_B43","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1213\/XAA.0000000000000621","article-title":"Eltrombopag to treat thrombocytopenia during last month of pregnancy in a woman with MYH9-related disease: a case report","volume":"10","author":"Favier","year":"2018","journal-title":"A A Pract"},{"issue":"3","key":"2019111616305145200_B44","doi-asserted-by":"crossref","first-page":"e793","DOI":"10.1542\/peds.2012-3807","article-title":"First successful use of eltrombopag before surgery in a child with MYH9-related thrombocytopenia","volume":"132","author":"Favier","year":"2013","journal-title":"Pediatrics"},{"issue":"11","key":"2019111616305145200_B45","doi-asserted-by":"crossref","first-page":"1367","DOI":"10.1182\/blood-2014-09-602573","article-title":"Effects of eltrombopag on platelet count and platelet activation in Wiskott-Aldrich syndrome\/X-linked thrombocytopenia","volume":"126","author":"Gerrits","year":"2015","journal-title":"Blood"},{"issue":"12","key":"2019111616305145200_B46","doi-asserted-by":"crossref","first-page":"1818","DOI":"10.1182\/blood-2013-10-534743","article-title":"Eltrombopag restores trilineage hematopoiesis in refractory severe aplastic anemia that can be sustained on discontinuation of drug","volume":"123","author":"Desmond","year":"2014","journal-title":"Blood"},{"issue":"25","key":"2019111616305145200_B47","doi-asserted-by":"crossref","first-page":"3906","DOI":"10.1182\/blood-2014-01-549360","article-title":"Eltrombopag and high-dose dexamethasone as frontline treatment of newly diagnosed immune thrombocytopenia in adults","volume":"123","author":"G\u00f3mez-Almaguer","year":"2014","journal-title":"Blood"}],"container-title":["Blood Advances"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/ashpublications.org\/bloodadvances\/article-pdf\/2\/4\/454\/880239\/advances010660.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/ashpublications.org\/bloodadvances\/article-pdf\/2\/4\/454\/880239\/advances010660.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,11,16]],"date-time":"2019-11-16T21:31:20Z","timestamp":1573939880000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article\/2\/4\/454\/15858\/Eltrombopag-for-use-in-children-with-immune"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,2,27]]},"references-count":47,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2018,2,27]]}},"URL":"https:\/\/doi.org\/10.1182\/bloodadvances.2017010660","relation":{},"ISSN":["2473-9529","2473-9537"],"issn-type":[{"value":"2473-9529","type":"print"},{"value":"2473-9537","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,2,27]]}}}